WO2011054553A1 - Benzodiazepine bromodomain inhibitor - Google Patents
Benzodiazepine bromodomain inhibitor Download PDFInfo
- Publication number
- WO2011054553A1 WO2011054553A1 PCT/EP2010/061518 EP2010061518W WO2011054553A1 WO 2011054553 A1 WO2011054553 A1 WO 2011054553A1 EP 2010061518 W EP2010061518 W EP 2010061518W WO 2011054553 A1 WO2011054553 A1 WO 2011054553A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- formula
- pharmaceutically acceptable
- acceptable salt
- methyl
- Prior art date
Links
- AAAQFGUYHFJNHI-SFHVURJKSA-N CCNC(C[C@@H]1N=C(c(cc2)ccc2Cl)c(cc(cc2)OC)c2-[n]2c1nnc2C)=O Chemical compound CCNC(C[C@@H]1N=C(c(cc2)ccc2Cl)c(cc(cc2)OC)c2-[n]2c1nnc2C)=O AAAQFGUYHFJNHI-SFHVURJKSA-N 0.000 description 1
- 0 COC(C[C@](*)C(Nc(c(C(c(cc1)ccc1Cl)=O)c1)ccc1OC)=O)=O Chemical compound COC(C[C@](*)C(Nc(c(C(c(cc1)ccc1Cl)=O)c1)ccc1OC)=O)=O 0.000 description 1
- MTCPJFMYZNHXOC-NRFANRHFSA-N Cc1nnc2[n]1-c(ccc(OC)c1)c1C(c(cc1)ccc1Cl)=N[C@H]2CC(NCCCCCN)=O Chemical compound Cc1nnc2[n]1-c(ccc(OC)c1)c1C(c(cc1)ccc1Cl)=N[C@H]2CC(NCCCCCN)=O MTCPJFMYZNHXOC-NRFANRHFSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the present invention relates to a benzodiazepine compound, processes for its preparation, pharmaceutical compositions containing such a compound and to its use in therapy.
- the genomes of eukaryotic organisms are highly organised within the nucleus of the cell.
- the long strands of duplex DNA are wrapped around an octomer of histone proteins (most usually comprising two copies of histones H2A, H2B H3 and H4) to form a nuclesome.
- This basic unit is then further compressed by the aggregation and folding of nucleosomes to form a highly condensed chromatin structure.
- a range of different states of condensation are possible, and the tightness of this structure varies during the cell cycle, being most compact during the process of cell division.
- Chromatin structure plays a critical role in regulating gene transcription, which cannot occur efficiently from highly condensed chromatin.
- the chromatin structure is controlled by a series of post translational modifications to histone proteins, notably histones H3 and H4, and most commonly within the histone tails which extend beyond the core nucleosome structure. These modifications include acetylation, methylation, phosphorylation, ubiquitinylation and SUMOylation. These epigenetic marks are written and erased by specific enzymes, which place the tags on specific residues within the histone tail, thereby forming an epigenetic code, which is then interpreted by the cell to allow gene specific regulation of chromatin structure and thereby transcription.
- Histone acetylation is most usually associated with the activation of gene transcription, as the modification loosens the interaction of the DNA and the histone octomer by changing the electrostatics.
- specific proteins bind to acetylated lysine residues within histones to read the epigenetic code.
- Bromodomains are small (-1 10 amino acid) distinct domains within proteins that bind to acetylated lysine resides commonly but not exclusively in the context of histones. There is a family of around 50 proteins known to contain bromodomains, and they have a range of functions within the cell.
- the Bet family of bromodomain containing proteins comprises 4 proteins (BRD2, BRD3, BRD4 and BRD-t) which contain tandem bromodomains capable of binding to two acetylated lysine resides in close proximity, increasing the specificity of the interaction.
- BRD2 and BRD3 are reported to associate with histones along actively transcribed genes and may be involved in facilitating transcriptional elongation (Leroy et al, Mol. Cell. 2008 30(1 ):51-60), while BRD4 appears to be involved in the recruitment of the pTEF-B complex to inducible genes, resulting in phosphorylation of RNA polymerase and increased transcriptional output (Hargreaves et al, Cell, 2009 138(1 ): 129-145).
- BRD4 and BRD3 fuse with NUT (nuclear protein in testis) forming a novel fusion oncogene, BRD4-NUT, in a highly malignant form of epithelial neoplasia (French et al. Cancer Research, 2003, 63, 304-307 and French et al. Journal of Clinical Oncology, 2004, 22 (20), 4135-4139).
- BRD-NUT fusion proteins contribute to carcinogensesis (Oncogene, 2008, 27, 2237-2242).
- BRD-t is uniquely expressed in the testes and ovary.
- Japanese patent application JP2008-15631 1 discloses a benzimidazole derivative which is said to be a BRD2 bromodomain binding agent which has utility with respect to virus infection / proliferation.
- Patent application WO2009/084693A1 discloses a series of thienotriazolodiazepiene derivatives that are said to inhibit the binding between an acetylated histone and a bromodomain containg protein which are said to be useful as anti-cancer agents.
- bromodomain inhibitor A compound which inhibits the binding of bromodomains with its cognate acetylated proteins, more particularly that inhibits the binding of Bet family bromodomains to acetylated lysine residues. Such a compound will hereafter be referred to as a "bromodomain inhibitor".
- a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable carriers, diluents or excipients.
- a compound of formula (I), or a pharmaceutically acceptable salt thereof for use in therapy, in particular in the treatment of diseases or conditions for which a bromodomain inhibitor is indicated.
- a method of treating diseases or conditions for which a bromodomain inhibitor is indicated in a subject in need thereof which comprises administering a therapeutically effective amount of compound of formula (I) or a pharmaceutically acceptable salt thereof.
- a compound of formula (I), or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of diseases or conditions for which a bromodomain inhibitor is indicated.
- the present invention relates to a compound of formula (I) which is 2-[(4S)-6-(4- Chlorophenyl)-1-methyl-8-(methyloxy)-4H-[1 ,2,4]triazolo[4,3-a][1 ,4]benzodiazepin-4-yl]-/V- ethylacetamide
- salts of the compounds of formula (I) are desirably pharmaceutically acceptable.
- Suitable pharmaceutically acceptable salts can include acid or base addition salts.
- a pharmaceutically acceptable salt may be readily prepared by using a desired acid or base as appropriate. The resultant salt may precipitate from solution and be collected by filtration or may be recovered by evaporation of the solvent.
- a pharmaceutically acceptable base addition salt can be formed by reaction of a compound of formula (I) with a suitable inorganic or organic base, (e.g. triethylamine, ethanolamine, triethanolamine, choline, arginine, lysine or histidine), optionally in a suitable solvent, to give the base addition salt which is usually isolated, for example, by crystallisation and filtration.
- a suitable inorganic or organic base e.g. triethylamine, ethanolamine, triethanolamine, choline, arginine, lysine or histidine
- Pharmaceutically acceptable base salts include ammonium salts, alkali metal salts such as those of sodium and potassium, alkaline earth metal salts such as those of calcium and magnesium and salts with organic bases, including salts of primary, secondary and tertiary amines, such as isopropylamine, diethylamine, ethanolamine, trimethylamine, dicyclohexyl amine and N-methyl-D-glucamine.
- a pharmaceutically acceptable acid addition salt can be formed by reaction of a compound of formula (I) with a suitable inorganic or organic acid (such as hydrobromic, hydrochloric, sulphuric, nitric, phosphoric, succinic, maleic, acetic, propionic, fumaric, citric, tartaric, lactic, benzoic, salicylic, glutamaic, aspartic, p-toluenesulfonic, benzenesulfonic, methanesulfonic, ethanesulfonic, naphthalenesulfonic such as 2- naphthalenesulfonic, or hexanoic acid), optionally in a suitable solvent such as an organic solvent, to give the salt which is usually isolated, for example, by crystallisation and filtration.
- a suitable inorganic or organic acid such as hydrobromic, hydrochloric, sulphuric, nitric, phosphoric, succinic, maleic,
- a pharmaceutically acceptable acid addition salt of a compound of formula (I) can comprise or be, for example, a hydrobromide, hydrochloride, sulfate, nitrate, phosphate, succinate, maleate, acetate, propionate, fumarate, citrate, tartrate, lactate, benzoate, salicylate, glutamate, aspartate, p-toluenesulfonate, benzenesulfonate, methanesulfonate, ethanesulfonate, naphthalenesulfonate (e.g. 2-naphthalenesulfonate) or hexanoate salt.
- the invention includes within its scope all possible stoichiometric and non-stoichiometric forms of the salts of the compound of formula (I).
- the invention includes within its scope all possible stoichiometric and non-stoichiometric forms of the solvates of the compound of formula (I).
- the invention encompasses all prodrugs, of the compound of formula (I) and pharmaceutically acceptable salts thereof, which upon administration to the recipient are capable of providing (directly or indirectly) a compound of formula (I) or a pharmaceutically acceptable salt thereof, or an active metabolite or residue thereof.
- Such derivatives are recognizable to those skilled in the art, without undue experimentation. Nevertheless, reference is made to the teaching of Burger's Medicinal Chemistry and Drug Discovery, 5 th Edition, Vol 1 : Principles and Practice, which is incorporated herein by reference to the extent of teaching such derivatives.
- the compound of formula (I) may be in crystalline or amorphous form. Furthermore, some of the crystalline forms of the compound of formula (I) may exist as polymorphs, which are included within the scope of the present invention. Polymorphic forms of the compound of formula (I) may be characterized and differentiated using a number of conventional analytical techniques, including, but not limited to, X-ray powder diffraction (XRPD) patterns, infrared (IR) spectra, Raman spectra, differential scanning calorimetry (DSC), thermogravimetric analysis (TGA) and solid state nuclear magnetic resonance (SSNMR).
- XRPD X-ray powder diffraction
- IR infrared
- Raman spectra Raman spectra
- DSC differential scanning calorimetry
- TGA thermogravimetric analysis
- SSNMR solid state nuclear magnetic resonance
- the compound of formula (I) is an individual isomer isolated such as to be substantially free of the other isomer (i.e. enantionerically
- Separation of isomers may be achieved by conventional techniques known to those skilled in the art, e.g. by fractional crystallisation, chromatography or HPLC.
- the compound of formula (I) may exist in one of several tautomeric forms. It will be understood that the present invention encompasses all tautomers of the compound of formula (I) whether as individual tautomers or as mixtures thereof.
- the compound of formula (I) and pharmaceutically acceptable salts thereof may be made by a variety of methods, including standard chemistry. Illustrative general synthetic methods are set out below and then the specific compound of formula (I) is prepared in the working Examples. These processes form further aspects of the present invention.
- the compound of formula (I) may be prepared according to reaction scheme 1 by reaction of a compound of formula (II) with EtNH 2 in the presence of HATU or HBTU and DIEA at room temperature.
- compounds of formula (I) may be prepared by reacting the compound of formula (II) with oxalyl chloride followed by addition of EtNH 2 in the presence of triethylamine.
- the compound of formula (II) may be prepared according to reaction Scheme 2.
- Suitable reaction conditions comprise reacting a compound of formula (III) with alkaline hydroxide preferably sodium hydroxide or lithium hydroxide.
- R represents C-
- Compounds of formula (IV) may be prepared according to reaction scheme 4 by reacting compounds of formula (VI) with hydrazine below 15 °C followed by reaction of the resulting hydrazone (V) with MeCOCI at 0°C. Generally hydrazone (V) is used without further purification and is reacted with MeCOCI at , for example 0 °C.
- Compounds of formula (VII) may be prepared according to reaction scheme 6, by reacting compounds of formula (IX) with an organic base such as triethylamine followed by reaction of the resulting amine (VIII) with acetic acid. Generally, amine (VIII) is used without further purification and is reacted with AcOH at, for example 60 °C.
- R represents C-
- the compound of formula (IIIA) may be prepared according to reaction scheme 9 by reacting compounds of formula (IVA) with EtNH 2 in the presence of HATU and DIEA at, for example room temperature.
- the compound of formula (IVA) may be prepared according to reaction scheme 10.
- Suitable reaction conditions comprise reacting compounds of formula (VI) with alkaline hydroxide such as sodium hydroxide.
- Suitable amine protecting groups include acyl (e.g. acetyl, carbamate (e.g. 2',2',2'- trichloroethoxycarbonyl, benzyloxycarbonyl or t-butoxycarbonyl) and arylalkyl (e.g. benzyl), which may be removed by hydrolysis (e.g.
- an acid such as hydrochloric acid in dioxane or trifluoroacetic acid in dichloromethane
- reductively e.g. hydrogenolysis of a benzyl or benzyloxycarbonyl group or reductive removal of a 2',2',2'- trichloroethoxycarbonyl group using zinc in acetic acid
- Other suitable amine protecting groups include trifluoroacetyl (-COCF 3 ) which may be removed by base catalysed hydrolysis.
- the compound of formula (I) and salts thereof is a bromodomain inhibitor, and thus is believed to have potential utility in the treatment of diseases or conditions for which a bromodomain is indicated.
- the present invention thus provides a compound of formula (I) or a pharmaceutically acceptable salt thereof for use in therapy.
- the compound of formula (I) or pharmaceutically salt thereof can be for use in the treatment of diseases or conditions for which a bromodomain inhibitor indicated.
- a compound of formula (I) or a pharmaceutically acceptable salt thereof for use in the treatment of diseases or conditions for which a bromodomain is indicated In another embodiment, there is provided a compound or a pharmaceutically acceptable salt thereof for use in the treatment of a chronic autoimmune and/or inflammatory condition. In a further embodiment, there is provided a compound or a pharmaceutically acceptable salt thereof for use in the treatment of cancer, such as midline carcinoma. In one embodiment there is provided the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of diseases or conditions for which a bromodomain inhibitor is indicated.
- a compound of formula (I) or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of a chronic autoimmune and/or inflammatory condition.
- a compound of formula (I) or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of cancer, such as midline carcinoma.
- a method for treatment of a disease or condition, for which a bromodomain inhibitor is indicated in a subject in need thereof which comprises administering a therapeutically effective amount of compound of formula (I) or a pharmaceutically acceptable salt thereof.
- a method for treatment of a chronic autoimmune and/or inflammatory condition in a subject in need thereof which comprises administering a therapeutically effective amount of compound of formula (I) or a pharmaceutically acceptable salt thereof.
- a method for treatment of cancer such as midline carcinoma, in a subject in need thereof which comprises administering a therapeutically effective amount of compound of formula (I) or a pharmaceutically acceptable salt thereof.
- the subject in need thereof is a mammal, particularly a human.
- the term "effective amount” means that amount of a drug or pharmaceutical agent that will elicit the biological or medical response of a tissue, system, animal or human that is being sought, for instance, by a researcher or clinician.
- therapeutically effective amount means any amount which, as compared to a corresponding subject who has not received such amount, results in improved treatment, healing, prevention, or amelioration of a disease, disorder, or side effect, or a decrease in the rate of advancement of a disease or disorder.
- the term also includes within its scope amounts effective to enhance normal physiological function.
- Bromodomain inhibitors are believed to be useful in the treatment of a variety of diseases or conditions related to systemic or tissue inflammation, inflammatory responses to infection or hypoxia, cellular activation and proliferation, lipid metabolism, fibrosis and in the prevention and treatment of viral infections.
- Bromodomain inhibitors may be useful in the treatment of a wide variety of chronic autoimmune and inflammatory conditions such as rheumatoid arthritis, osteoarthritis, acute gout, psoriasis, systemic lupus erythematosus, multiple sclerosis, inflammatory bowel disease (Crohn's disease and Ulcerative colitis), asthma, chronic obstructive airways disease, pneumonitis, myocarditis, pericarditis, myositis, eczema, dermatitis, alopecia, vitiligo, bullous skin diseases, nephritis, vasculitis, atherosclerosis, Alzheimer's disease, depression, retinitis, uveitis, scleritis, hepatitis, pancreatitis, primary biliary cirrhosis, sclerosing cholangitis, Addison's disease, hypophysitis, thyroiditis, type I diabetes and
- Bromodomain inhibitors may be useful in the treatment of a wide variety of acute inflammatory conditions such as acute gout, giant cell arteritis, nephritis including lupus nephritis, vasculitis with organ involvement such as glomerulonephritis, vasculitis including giant cell arteritis, Wegener's granulomatosis, Polyarteritis nodosa, Behcet's disease, Kawasaki disease, Takayasu's Arteritis and acute rejection of transplanted organs.
- acute inflammatory conditions such as acute gout, giant cell arteritis, nephritis including lupus nephritis, vasculitis with organ involvement such as glomerulonephritis, vasculitis including giant cell arteritis, Wegener's granulomatosis, Polyarteritis nodosa, Behcet's disease, Kawasaki disease, Takayasu's Arte
- Bromodomain inhibitors may be useful in the prevention or treatment of diseases or conditions which involve inflammatory responses to infections with bacteria, viruses, fungi, parasites or their toxins, such as sepsis, sepsis syndrome, septic shock, endotoxaemia, systemic inflammatory response syndrome (SIRS), multi-organ dysfunction syndrome, toxic shock syndrome, acute lung injury, ARDS (adult respiratory distress syndrome), acute renal failure, fulminant hepatitis, burns, acute pancreatitis, post-surgical syndromes, sarcoidosis, Herxheimer reactions, encephalitis, myelitis, meningitis, malaria, SIRS associated with viral infections such as influenza, herpes zoster, herpes simplex and coronavirus.
- SIRS systemic inflammatory response syndrome
- multi-organ dysfunction syndrome toxic shock syndrome
- acute lung injury ARDS (adult respiratory distress syndrome)
- ARDS adult respiratory distress syndrome
- fulminant hepatitis burns
- acute pancreatitis
- Bromodomain inhibitors may be useful in the prevention or treatment of conditions associated with ischaemia-reperfusion injury such as myocardial infarction, cerebrovascular ischaemia (stroke), acute coronary syndromes, renal reperfusion injury, organ transplantation, coronary artery bypass grafting, cardio-pulmonary bypass procedures and pulmonary, renal, hepatic, gastro-intestinal or peripheral limb embolism.
- ischaemia-reperfusion injury such as myocardial infarction, cerebrovascular ischaemia (stroke), acute coronary syndromes, renal reperfusion injury, organ transplantation, coronary artery bypass grafting, cardio-pulmonary bypass procedures and pulmonary, renal, hepatic, gastro-intestinal or peripheral limb embolism.
- Bromodomain inhibitors may be useful in the treatment of disorders of lipid metabolism via the regulation of APO-A1 such as hypercholesterolemia, atherosclerosis and Alzheimer's disease. Bromodomain inhibitors may be useful in the treatment of fibrotic conditions such as idiopathic pulmonary fibrosis, renal fibrosis, post-operative stricture, keloid formation, scleroderma and cardiac fibrosis.
- Bromodomain inhibitors may be useful in the prevention and treatment of viral infections such as herpes virus, human papilloma virus, adenovirus, poxvirus and other DNA viruses.
- Bromodomain inhibitors may be useful in the treatment of cancer, including hematological (such as leukaemia), epithelial including lung, breast and colon carcinomas, midline carcinomas, mesenchymal, hepatic, renal and neurological tumours.
- Bromodomain inhibitors may be useful in the treatment of treatment of ophthamological indications such as dry eye.
- the disease or condition for which a bromodomain inhibitor is indicated is selected from diseases associated with systemic inflammatory response syndrome, such as sepsis, burns, pancreatitis, major trauma, haemorrhage and ischaemia.
- the bromodomain inhibitor would be administered at the point of diagnosis to reduce the incidence of: SIRS, the onset of shock, multi-organ dysfunction syndrome, which includes the onset of acute lung injury, ARDS, acute renal, hepatic, cardiac and gastro-intestinal injury and mortality.
- the bromodomain inhibitor would be administered prior to surgical or other procedures associated with a high risk of sepsis, haemorrhage, extensive tissue damage, SIRS or MODS.
- the disease or condition for which a bromodomain inhibitor is indicated is sepsis, sepsis syndrome, septic shock and/or endotoxaemia.
- the bromodomain inhibitor is indicated for the treatment of acute or chronic pancreatitis.
- the bromodomain is indicated for the treatment of burns.
- the disease or condition for which a bromodomain inhibitor is indicated is selected from herpes simplex infections and reactivations, cold sores, herpes zoster infections and reactivations, chickenpox, shingles, human papilloma virus, cervical neoplasia, adenovirus infections, including acute respiratory disease, and poxvirus infections such as cowpox and smallpox and African swine fever virus.
- a bromodomain inhibitor is indicated for the treatment of Human papilloma virus infections of skin or cervical epithelia.
- a compound of formula (I) as well as pharmaceutically acceptable salts thereof may be administered as the raw chemical, it is common to present the active ingredient as a pharmaceutical composition.
- the present invention therefore provides in a further aspect a pharmaceutical composition
- a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable carriers, diluents or excipients.
- a pharmaceutical composition for the treatment of diseases or conditions in which a bromodomain inhibitor is indicated comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof.
- the carrier(s), diluent(s) or excipient(s) used in such pharmaceutical compositions must be acceptable in the sense of being compatible with the other ingredients of the composition and not deleterious to the recipient thereof.
- a process for the preparation of a pharmaceutical composition including admixing a compound of formula (I), or a pharmaceutically acceptable salt thereof, with one or more pharmaceutically acceptable carriers, diluents or excipients.
- the pharmaceutical composition can be for use in the treatment of any of the conditions described herein.
- the compound of formula (I) and pharmaceutically acceptable salts thereof are intended for use in pharmaceutical compositions it will be readily understood that they are each preferably provided in substantially pure form, for example, at least 60% pure, more suitably at least 75% pure and preferably at least 85% pure, especially at least 98% pure (% in a weight for weight basis).
- compositions may be presented in unit dose forms containing a predetermined amount of active ingredient per unit dose.
- Preferred unit dosage compositions are those containing a daily dose or sub-dose, or an appropriate fraction thereof, of an active ingredient. Such unit doses may therefore be administered more than once a day.
- Preferred unit dosage compositions are those containing a daily dose or sub-dose (for administration more than once a day), as herein above recited, or an appropriate fraction thereof, of an active ingredient.
- compositions may be adapted for administration by any appropriate route, for example by the oral (including buccal or sublingual), rectal, inhaled, intranasal, topical (including buccal, sublingual or transdermal), vaginal or parenteral (including subcutaneous, intramuscular, intravenous or intradermal) route.
- Such compositions may be prepared by any method known in the art of pharmacy, for example by bringing into association the active ingredient with the carrier(s) or excipient(s).
- the pharmaceutical composition is adapted for oral administration. In one embodiment the pharmaceutical composition is adapted for parenteral administration, particularly intravenous administration.
- compositions adapted for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the composition isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents.
- the compositions may be presented in unit- dose or multi-dose containers, for example sealed ampoules and vials, and may be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example water for injections, immediately prior to use.
- Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets.
- compositions adapted for oral administration may be presented as discrete units such as capsules or tablets; powders or granules; solutions or suspensions in aqueous or non-aqueous liquids; edible foams or whips; or oil-in-water liquid emulsions or water-in-oil liquid emulsions.
- the active drug component can be combined with an oral, non-toxic pharmaceutically acceptable inert carrier such as ethanol, glycerol, water and the like.
- an oral, non-toxic pharmaceutically acceptable inert carrier such as ethanol, glycerol, water and the like.
- Powders suitable for incorporating into tablets or capsules may be prepared by reducing the compound to a suitable fine size (e.g. by micronisation) and mixing with a similarly prepared pharmaceutical carrier such as an edible carbohydrate, as, for example, starch or mannitol. Flavoring, preservative, dispersing and coloring agent can also be present.
- Capsules may be made by preparing a powder mixture, as described above, and filling formed gelatin sheaths.
- Glidants and lubricants such as colloidal silica, talc, magnesium stearate, calcium stearate or solid polyethylene glycol can be added to the powder mixture before the filling operation.
- a disintegrating or solubilizing agent such as agar- agar, calcium carbonate or sodium carbonate can also be added to improve the availability of the medicament when the capsule is ingested.
- suitable binders include starch, gelatin, natural sugars such as glucose or beta-lactose, corn sweeteners, natural and synthetic gums such as acacia, tragacanth or sodium alginate, carboxymethylcellulose, polyethylene glycol, waxes and the like.
- Lubricants used in these dosage forms include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride and the like.
- Disintegrators include, without limitation, starch, methyl cellulose, agar, bentonite, xanthan gum and the like. Tablets are formulated, for example, by preparing a powder mixture, granulating or slugging, adding a lubricant and disintegrant and pressing into tablets.
- a powder mixture is prepared by mixing the compound, suitably comminuted, with a diluent or base as described above, and optionally, with a binder such as carboxymethylcellulose, an aliginate, gelatin, or polyvinyl pyrrolidone, a solution retardant such as paraffin, a resorption accelerator such as a quaternary salt and/or an absorption agent such as bentonite, kaolin or dicalcium phosphate.
- the powder mixture can be granulated by wetting with a binder such as syrup, starch paste, acadia mucilage or solutions of cellulosic or polymeric materials and forcing through a screen.
- the powder mixture can be run through the tablet machine and the result is imperfectly formed slugs broken into granules.
- the granules can be lubricated to prevent sticking to the tablet forming dies by means of the addition of stearic acid, a stearate salt, talc or mineral oil.
- the lubricated mixture is then compressed into tablets.
- the compounds of the present invention can also be combined with a free flowing inert carrier and compressed into tablets directly without going through the granulating or slugging steps.
- a clear or opaque protective coating consisting of a sealing coat of shellac, a coating of sugar or polymeric material and a polish coating of wax can be provided. Dyestuffs can be added to these coatings to distinguish different unit dosages.
- Oral fluids such as solution, syrups and elixirs can be prepared in dosage unit form so that a given quantity contains a predetermined amount of the compound.
- Syrups can be prepared by dissolving the compound in a suitably flavored aqueous solution, while elixirs are prepared through the use of a non-toxic alcoholic vehicle.
- Suspensions can be formulated by dispersing the compound in a non-toxic vehicle.
- Solubilizers and emulsifiers such as ethoxylated isostearyl alcohols and polyoxy ethylene sorbitol ethers, preservatives, flavor additive such as peppermint oil or natural sweeteners or saccharin or other artificial sweeteners, and the like can also be added.
- dosage unit compositions for oral administration can be microencapsulated.
- the formulation can also be prepared to prolong or sustain the release as for example by coating or embedding particulate material in polymers, wax or the like.
- the compounds of formula (I) and pharmaceutically acceptable salts thereof can also be administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles.
- Liposomes can be formed from a variety of phospholipids, such as cholesterol, stearylamine or phosphatidylcholines.
- compositions adapted for topical administration may be formulated as ointments, creams, suspensions, lotions, powders, solutions, pastes, gels, sprays, aerosols or oils.
- compositions are preferably applied as a topical ointment or cream.
- the active ingredient may be employed with either a paraffinic or a water- miscible ointment base.
- the active ingredient may be formulated in a cream with an oil-in-water cream base or a water-in-oil base.
- compositions adapted for topical administrations to the eye include eye drops wherein the active ingredient is dissolved or suspended in a suitable carrier, especially an aqueous solvent.
- a suitable carrier especially an aqueous solvent.
- Dosage forms for nasal or inhaled administration may conveniently be formulated as aerosols, solutions, suspensions, gels or dry powders.
- compositions suitable and/or adapted for inhaled administration it is preferred that the compound of formula (I) or pharmaceutically acceptable salt thereof is in a particle-size- reduced form e.g. obtained by micronisation.
- the preferable particle size of the size- reduced (e.g. micronised) compound or salt is defined by a D50 value of about 0.5 to about 10 microns (for example as measured using laser diffraction).
- Aerosol formulations, e.g. for inhaled administration can comprise a solution or fine suspension of the active substance in a pharmaceutically acceptable aqueous or nonaqueous solvent.
- Aerosol formulations can be presented in single or multidose quantities in sterile form in a sealed container, which can take the form of a cartridge or refill for use with an atomising device or inhaler.
- the sealed container may be a unitary dispensing device such as a single dose nasal inhaler or an aerosol dispenser fitted with a metering valve (metered dose inhaler) which is intended for disposal once the contents of the container have been exhausted.
- the dosage form comprises an aerosol dispenser
- it preferably contains a suitable propellant under pressure such as compressed air, carbon dioxide or an organic propellant such as a hydrofluorocarbon (HFC).
- suitable HFC propellants include
- the aerosol dosage forms can also take the form of a pump-atomiser.
- the pressurised aerosol may contain a solution or a suspension of the active compound. This may require the incorporation of additional excipients e.g. co-solvents and/or surfactants to improve the dispersion characteristics and homogeneity of suspension formulations. Solution formulations may also require the addition of co-solvents such as ethanol.
- the pharmaceutical composition may be a dry powder inhalable composition.
- a dry powder inhalable composition can comprise a powder base such as lactose, glucose, trehalose, mannitol or starch, the compound of formula (I) or a pharmaceutically acceptable salt thereof (preferably in particle-size-reduced form, e.g. in micronised form), and optionally a performance modifier such as L-leucine or another amino acid and/or metals salts of stearic acid such as magnesium or calcium stearate.
- the dry powder inhalable composition comprises a dry powder blend of lactose e.g. lactose monohydrate and the compound of formula (I) or a pharmaceutically acceptable salt thereof.
- Such compositions can be administered to the patient using a suitable device such as the
- DISKUS® device marketed by GlaxoSmithKline which is for example described in GB 2242134 A.
- the compound of formula (I) and pharmaceutically acceptable salts thereof thereof may be formulated as a fluid formulation for delivery from a fluid dispenser, for example a fluid dispenser having a dispensing nozzle or dispensing orifice through which a metered dose of the fluid formulation is dispensed upon the application of a user-applied force to a pump mechanism of the fluid dispenser.
- a fluid dispenser for example a fluid dispenser having a dispensing nozzle or dispensing orifice through which a metered dose of the fluid formulation is dispensed upon the application of a user-applied force to a pump mechanism of the fluid dispenser.
- Such fluid dispensers are generally provided with a reservoir of multiple metered doses of the fluid formulation, the doses being dispensable upon sequential pump actuations.
- the dispensing nozzle or orifice may be configured for insertion into the nostrils of the user for spray dispensing of the fluid formulation into the nasal cavity.
- a fluid dispenser of the aforementioned type is described and illustrated in WO2005/044354
- each dosage unit for oral or parenteral administration preferably contains from 0.01 to 3000 mg, more preferably 0.5 to 1000 mg, of a compound of formula (I) or pharmaceutically acceptable salt thereof calculated as the free base.
- Each dosage unit for nasal or inhaled administration preferably contains from 0.001 to 50 mg, more preferably 0.01 to 5 mg, of a compound of the formula (I) or a pharmaceutically acceptable salt thereof, calculated as the free base.
- the compound of formula (I) and pharmaceutically acceptable salts thereof can be administered in a daily dose (for an adult patient) of, for example, an oral or parenteral dose of 0.01 mg to 3000 mg per day or 0.5 to 1000 mg per day, or a nasal or inhaled dose of 0.001 to 50 mg per day or 0.01 to 5 mg per day, of the compound of formula (I) or a pharmaceutically acceptable salt thereof, calculated as the free base.
- This amount may be given in a single dose per day or more usually in a number (such as two, three, four, five or six) of sub-doses per day such that the total daily dose is the same.
- An effective amount of a pharmaceutically acceptable salt thereof may be determined as a proportion of the effective amount of the compound of formula (I) per se.
- composition comprising a) 0.01 to 3000mg of a compound of formula (I) or a pharmaceutically acceptable salt thereof, and (b) 0.1 to 2g of one or more pharamceutically acceptable carriers, diluents and/or excipients.
- Combination therapies according to the present invention thus comprise the administration of at least one compound of formula (I) or a pharmaceutically acceptable salt thereof, and the use of at least one other pharmaceutically active agent.
- combination therapies according to the present invention comprise the administration of at least one compound of formula (I) or a pharmaceutically acceptable salt thereof, and at least one other pharmaceutically active agent.
- the compoundof formula (I) and pharmaceutically acceptable salts thereof, and the other pharmaceutically active agent(s) may be administered together in a single pharmaceutical composition or separately and, when administered separately this may occur simultaneously or sequentially in any order.
- a combination comprising a compound of formula (I) or pharmaceutically acceptable salt thereof and at least one other pharmaceutically active agent.
- a combination pharmaceutical product comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof together with one or more other therapeutically active agents.
- the compound of formula (I) and pharmaceutical compositions according to the invention may be used in combination with or include one or more other therapeutic agents, for example selected from antibiotics, anti-virals, glucocorticosteroids, muscarinic antagonists and beta-2 agonists.
- one or more other therapeutic agents for example selected from antibiotics, anti-virals, glucocorticosteroids, muscarinic antagonists and beta-2 agonists.
- the compound of formula (I) and pharmaceutically acceptable sdalt thereof are administered in combination with other therapeutic agents normally administered by the inhaled, intravenous, oral or intranasal route, that the resultant pharmaceutical composition may be administered by the same routes. Alternatively the individual components of the composition may be administered by different routes.
- One embodiment of the invention encompasses combinations comprising one or two other therapeutic agents.
- the other therapeutic ingredient(s) may be used in the form of salts, for example as alkali metal or amine salts or as acid addition salts, or prodrugs, or as esters, for example lower alkyl esters, or as solvates, for example hydrates, to optimise the activity and/or stability and/or physical characteristics, such as solubility, of the therapeutic ingredient.
- the therapeutic ingredients may be used in optically pure form.
- the combinations referred to above may conveniently be presented for use in the form of a pharmaceutical composition and thus pharmaceutical compositions comprising a combination as defined above together with a pharmaceutically acceptable diluent or carrier represent a further aspect of the invention.
- the compound of formula (I) may be prepared by the methods described below or by similar methods. Thus the following Intermediates and Examples serve to illustrate the preparation of the compound of formula (I) and is not to be considered as limiting the scope of the invention in any way.
- LC/MS refers to analyses by analytical HPLC which were conducted on two kinds of apparatus:
- MS mass spectra
- electrospray positive ionisation (ES+ve to give [M+H] + and [M+NH4] + molecular ions] or electrospray negative ionisation [(ES-ve to give [M-H]- molecular ion] modes.
- Analytical data from this apparatus are given with the following format : [M+H] + or [M-H] " .
- LC/HRMS Analytical HPLC was conducted on a Uptisphere-hsc column (3 ⁇ 33 x 3 mm id) eluting with 0.01 M ammonium acetate in water (solvent A) and 100% acetonitrile (solvent B), using the following elution gradient 0-0.5 minutes 5% B, 0.5-3.75 minutes 5 ⁇ 100% B, 3.75-4.5 100% B, 4.5-5 100 ⁇ 5% B, 5-5.5 5% B at a flow rate of 1 .3 mL/minute.
- MS mass spectra
- Mass directed auto-prep HPLC refers to the method where the material was purified by high performance liquid chromatography on a HPLCABZ+ 5 ⁇ column (5cm x 10mm i.d.) with 0.1 % HCO2H in water and 95% MeCN, 5% water (0.5% HCO2H) utilising the following gradient elution conditions: 0-1.0 minutes 5%B, 1.0-8.0 minutes 5 ⁇ 30%B, 8.0- 8.9 minutes 30%B, 8.9-9.0 minutes 30 ⁇ 95%B, 9.0-9.9 minutes 95%B, 9.9-10 minutes 95 ⁇ 0%B at a flow rate of 8mL/minute.
- the Gilson 202-fraction collector was triggered by a VG Platform Mass Spectrometer on detecting the mass of interest.
- TLC thin layer chromatography refers to the use of TLC plates sold by Merck coated with silica gel 60 F254.
- Example 1 2-[(4S)-6-(4-Chlorophenyl)-1 -methyl-8-(methyloxy)-4H-[1 ,2,4]triazolo[4,3-
- the crude material was suspended in water and extracted with DCM. The organic layer was dried over Na 2 S0 4 , filtered and concentrated in vacuo. The crude solid was purified by chromatography on Si0 2 (DCM/MeOH 95/5) and the resulting solid recrystallised in MeCN. The solid was then dissolved in DCM and precipited with / ' -Pr 2 0 to give the title compound (8 g, 47% yield) as a white solid.
- LC/MS (Method A) was conducted on a Supelcosil LCABZ+PLUS column (3 ⁇ , 3.3cm x 4.6mm ID) eluting with 0.1 % HCO2H and 0.01 M ammonium acetate in water (solvent A), and 95% acetonitrile and 0.05% HCO2H in water (solvent B), using the following elution gradient 0-0.7 minutes 0%B, 0.7-4.2 minutes 0 ⁇ 100%B, 4.2-5.3 minutes 100%B, 5.3-5.5 minutes 100 ⁇ 0%B at a flow rate of 3 mL/minute.
- MS mass spectra
- LC/MS (Method B) was conducted on an Sunfire C18 column (30mm x 4.6mm i.d. 3.5 ⁇ packing diameter) at 30 degrees centigrade, eluting with 0.1 % v/v solution of Trifluoroacetic Acid in Water (Solvent A) and 0.1 % v/v solution of Trifluoroacetic Acid in Acetonitrile (Solvent B) using the following elution gradient 0-0.1 min 3%B, 0.1- 4.2min 3 - 100% B, 4.2-4.8min 100% B, 4.8-4.9min 100-3%B, 4.9 - 5.0min 3% B at a flow rate of 3ml/min.
- LC/HRMS Analytical HPLC was conducted on a Uptisphere-hsc column (3 ⁇ 33 x 3 mm id) eluting with 0.01 M ammonium acetate in water (solvent A) and 100% acetonitrile (solvent B), using the following elution gradient 0-0.5 minutes 5% B, 0.5-3.75 minutes 5 ⁇ 100% B, 3.75-4.5 100% B, 4.5-5 100 ⁇ 5% B, 5-5.5 5% B at a flow rate of 1 .3 mL/minute.
- MS mass spectra
- TLC thin layer chromatography
- Silica chromatography techniques include either automated (Flashmaster or Biotage SP4) techniques or manual chromatography on pre-packed cartridges (SPE) or manually- packed flash columns.
- Reference compound B [2-amino- -(methyloxy)phenyl](4-chlorophenyl)methanone
- Reference compound I 1 ,1 -dimethylethyl [5-( ⁇ [(4S)-6-(4-chlorophenyl)-1 -methyl-8- (methyloxy)-4H-[1 ,2,4]triazolo[4,3-a][1 ,4]benzodiazepin-4- yl]acetyl ⁇ amino)pentyl]carbamate
- Reference compound K Mixture of 5- and 6- isomers of Alexa Fluor 488-N-(5- aminopentyl)-2-[(4S)-6-(4-chlorophenyl)-1 -methyl-8-(methyloxy)-4H- [1 ,2,4]triazolo[4,3-a][1 ,4]benzodiazepin-4-yl]acetamide
- N-(5-aminopentyl)-2-[(4S)-6-(4-chlorophenyl)-1 -methyl-8-(methyloxy)-4H- [1 ,2,4]triazolo[4,3-a][1 ,4]benzodiazepin-4-yl]acetamide trifluoroacetate (for a preparation see Reference compound J)(7.65 mg, 0.013 mmol) was dissolved in N,N- Dimethylformamide (DMF) (300 ⁇ ) and added to Alexa Fluor 488 carboxylic acid succinimidyl ester (5 mg, 7.77 ⁇ , mixture of 5 and 6 isomers, available from Invitrogen, product number A-20100) in an Eppendorf centrifuge tube.
- DMF N,N- Dimethylformamide
- the Bromodomain protein, fluorescent ligand (Reference compound K see above) and a variable concentration of test compound are incubated together to reach thermodynamic equilibrium under conditions such that in the absence of test compound the fluorescent ligand is significantly (>50%) bound and in the presence of a sufficient concentration of a potent inhibitor the anisotropy of the unbound fluorescent ligand is measurably different from the bound value.
- 'a' is the minimum
- 'b' is the Hill slope
- 'c' is the plC50
- 'd' is the maximum.
- Recombinant Human Bromodomains (Bromodomain 2 (1-473), Bromodomain 3 (1-435) and Bromodomain 4 (1-477)) were expressed in E.coli cells (in pET15b vector) with a six- His tag at the N-terminal.
- the His-tagged Bromodomain was extracted from E.coli cells using 0.1 mg/ml lysozyme and sonication.
- the Bromodomain was then purified by affinity chromatography on a HisTRAP HP column, eluting with a linear 10-500mM Imidazole gradient, over 20 Cv. Further purification was completed by Superdex 200 prep grade size exclusion column. Purified protein was stored at -80C in 20mM HEPES pH 7.5 and l OOmM NaCI.
- Example 1 had a plC50 ⁇ 6.0 in each of the BRD2, BRD3 and BRD4 assays described above. LPS stimulated Whole Blood measuring TNFa levels assay
- Activation of monocytic cells by agonists of toll-like receptors such as bacterial lipopolysaccharide (LPS) results in production of key inflammatory mediators including TNFa.
- LPS bacterial lipopolysaccharide
- TNFa levels assayed by immunoassay (typically by MesoScale Discovery technology) either immediately or following storage at -20 degrees.
- Dose response curves for each compound was generated from the data and an IC50 value was calculated.
- Example 1 was found to have a plC50 > 6.0 in the above assay.
- Example 1 tested in the above assay inhibited the production of the key inflammatory mediator TNFa. This suggests that such a compound has a strong anti-inflammatory profile, which is likely to translate into clinical benefit in inflammatory disorders.
- Endotoxin bacterial lipopolysaccharide
- Endotoxin bacterial lipopolysaccharide
- This pattern of response is very similar to human sepsis and septic shock, where the body's response to a significant bacterial infection can be similarly life threatening.
- mice were given a lethal dose of 15 mg/kg LPS by intraperitoneal injection.
- animals were dosed intravenously with vehicle (20% cyclodextrin 1 % ethanol in apyrogen water) or compound (10 mg/kg). The survival of animals was monitored at 4 days.
- Example 1 tested in the above model gave rise to a significant animal survival effect following intravenous administration. This suggests that the compound of formula (I) has the potential for a profound effect on inflammatory responses in humans.
Abstract
Description
Claims
Priority Applications (56)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MX2012005295A MX2012005295A (en) | 2009-11-05 | 2010-08-06 | Benzodiazepine bromodomain inhibitor. |
DK10740654.8T DK2496580T3 (en) | 2009-11-05 | 2010-08-06 | Benzodiazepine bromine domain inhibitor |
BR112012010706A BR112012010706A2 (en) | 2009-11-05 | 2010-08-06 | compound, pharmaceutical composition, pharmaceutical combination, use of a compound, and methods for treating a disease or condition, and for inhibiting bromodomain |
SI201030514T SI2496580T1 (en) | 2009-11-05 | 2010-08-06 | Benzodiazepine bromodomain inhibitor |
AU2010314395A AU2010314395B2 (en) | 2009-11-05 | 2010-08-06 | Benzodiazepine bromodomain inhibitor |
CN201080050285.XA CN102762569B (en) | 2009-11-05 | 2010-08-06 | Benzodiazepine bromodomain inhibitor |
RS20140088A RS53179B (en) | 2009-11-05 | 2010-08-06 | Benzodiazepine bromodamain inhibitor |
KR1020127014637A KR101424989B1 (en) | 2009-11-05 | 2010-08-06 | Benzodiazepine bromodomain inhibitor |
JP2012537329A JP5524343B2 (en) | 2009-11-05 | 2010-08-06 | Benzodiazepine bromodomain inhibitor |
NZ599258A NZ599258A (en) | 2009-11-05 | 2010-08-06 | Benzodiazepine bromodomain inhibitor |
US13/505,039 US9023842B2 (en) | 2009-11-05 | 2010-08-06 | Benzodiazepine bromodomain inhibitor |
UAA201205470A UA105675C2 (en) | 2009-11-05 | 2010-08-06 | Benzodiazepine bromodomain inhibitor |
EA201290183A EA020390B1 (en) | 2009-11-05 | 2010-08-06 | Benzodiazepine bromodomain inhibitor |
CA2779355A CA2779355C (en) | 2009-11-05 | 2010-08-06 | Benzodiazepine bromodomain inhibitor |
EP10740654.8A EP2496580B1 (en) | 2009-11-05 | 2010-08-06 | Benzodiazepine bromodomain inhibitor |
PL10740654T PL2496580T3 (en) | 2009-11-05 | 2010-08-06 | Benzodiazepine bromodomain inhibitor |
ES10740654.8T ES2446647T3 (en) | 2009-11-05 | 2010-08-06 | Benzodiazepine Bromodomain Inhibitor |
CN201080060697.1A CN102781943B (en) | 2009-11-05 | 2010-11-03 | Benzodiazepine * bromine domain inhibitor |
US13/504,971 US9102677B2 (en) | 2009-11-05 | 2010-11-03 | Benzodiazepine bromodomain inhibitor |
EP16152464.0A EP3050885B1 (en) | 2009-11-05 | 2010-11-03 | Benzodiazepine bromodomain inhibitor |
PL10773325T PL2496582T3 (en) | 2009-11-05 | 2010-11-03 | Benzodiazepine bromodomain inhibitor |
DK10773325.5T DK2496582T3 (en) | 2009-11-05 | 2010-11-03 | Benzodiazepine-BROMDOMAeNEINHIBITOR. |
HUE10773325A HUE026967T2 (en) | 2009-11-05 | 2010-11-03 | Benzodiazepine bromodomain inhibitor |
SI201031143T SI2496582T1 (en) | 2009-11-05 | 2010-11-03 | Benzodiazepine bromodomain inhibitor |
KR1020127014635A KR20120097508A (en) | 2009-11-05 | 2010-11-03 | Benzodiazepine bromodomain inhibitor |
CA2779423A CA2779423C (en) | 2009-11-05 | 2010-11-03 | Benzodiazepine bromodomain inhibitor |
JP2012537381A JP5702396B2 (en) | 2009-11-05 | 2010-11-03 | Benzodiazepine bromodomain inhibitor |
MEP-2016-52A ME02356B (en) | 2009-11-05 | 2010-11-03 | Benzodiazepine bromodomain inhibitor |
EP10773325.5A EP2496582B1 (en) | 2009-11-05 | 2010-11-03 | Benzodiazepine bromodomain inhibitor |
AU2010317096A AU2010317096B2 (en) | 2009-11-05 | 2010-11-03 | Benzodiazepine bromodomain inhibitor |
BR112012010705A BR112012010705A2 (en) | 2009-11-05 | 2010-11-03 | compound, pharmaceutical composition, combined pharmaceutical product, use of a compound, and methods for treating a disease or condition, and for inhibiting bromodomain |
RS20160190A RS54645B1 (en) | 2009-11-05 | 2010-11-03 | Benzodiazepine bromodomain inhibitor |
PCT/EP2010/066697 WO2011054845A1 (en) | 2009-11-05 | 2010-11-03 | Benzodiazepine bromodomain inhibitor |
MX2012005296A MX341212B (en) | 2009-11-05 | 2010-11-03 | Benzodiazepine bromodomain inhibitor. |
ES16152464.0T ES2654423T3 (en) | 2009-11-05 | 2010-11-03 | Benzodiazepine Bromodomain Inhibitor |
EA201290184A EA023441B1 (en) | 2009-11-05 | 2010-11-03 | Benzodiazepine bromodomain inhibitor |
ES10773325.5T ES2564318T3 (en) | 2009-11-05 | 2010-11-03 | Benzodiazepine Bromodomain Inhibitor |
IL219090A IL219090A0 (en) | 2009-11-05 | 2012-04-05 | Benzodiazepine bromodomain inhibitor |
IL219253A IL219253A (en) | 2009-11-05 | 2012-04-18 | Benzodiazepine bromodomain inhibitor for use in the treatment of cancer |
MA34934A MA33803B1 (en) | 2009-11-05 | 2012-06-04 | BENZODIAZEPINE BROMODOMAINE INHIBITOR |
HK13102225.8A HK1175458A1 (en) | 2009-11-05 | 2013-02-21 | Benzodiazepine bromodomain inhibitor |
HRP20140107AT HRP20140107T1 (en) | 2009-11-05 | 2014-02-05 | Benzodiazepine bromodomain inhibitor |
SM201400024T SMT201400024B (en) | 2009-11-05 | 2014-02-20 | Bromodomain inhibitor of benzodiazepines |
IL235983A IL235983B (en) | 2009-11-05 | 2014-11-30 | 2-[(4s)-6-(4-chlorophenyl)-1-methyl-8-(methyloxy)-4h-s-triazolo[4,3-a][1,4]benzodiazepin-4-yl]-n-ethylacetamide, salts thereof and pharmaceutical compositions comprising them |
JP2015030132A JP2015143232A (en) | 2009-11-05 | 2015-02-19 | Benzodiazepine bromodomain inhibitor |
US14/684,659 US20150210706A1 (en) | 2009-11-05 | 2015-04-13 | Benzodiazepine Bromodomain Inhibitor |
AU2015203454A AU2015203454B2 (en) | 2009-11-05 | 2015-06-23 | Benzodiazepine bromodomain inhibitor |
IL239625A IL239625B (en) | 2009-11-05 | 2015-06-25 | Benzodiazepine bromodomain inhibitor |
US14/753,326 US9598420B2 (en) | 2009-11-05 | 2015-06-29 | Benzodiazepine bromodomain inhibitor |
HRP20160253TT HRP20160253T1 (en) | 2009-11-05 | 2016-03-10 | Benzodiazepine bromodomain inhibitor |
SM201600081T SMT201600081B (en) | 2009-11-05 | 2016-03-22 | BENZODIAZEPINE BROMODOMYN INHIBITOR |
SM201600104T SMT201600104B (en) | 2009-11-05 | 2016-04-13 | BENZODIAZEPIN BROMODOMYN INHIBITOR |
HK16109359.8A HK1221221A1 (en) | 2009-11-05 | 2016-08-05 | Benzodiazepine bromodomain inhibitor |
JP2016185487A JP2017039738A (en) | 2009-11-05 | 2016-09-23 | Benzodiazepine bromodomain inhibitor |
US15/410,874 US20170197972A1 (en) | 2009-11-05 | 2017-01-20 | Benzodiazepine bromodomain inhibitor |
US15/426,294 US20170145021A1 (en) | 2009-11-05 | 2017-02-07 | Novel compounds |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0919433.3 | 2009-11-05 | ||
GB0919433A GB0919433D0 (en) | 2009-11-05 | 2009-11-05 | Novel compounds |
GBGB1010509.6A GB201010509D0 (en) | 2010-06-22 | 2010-06-22 | Novel compounds |
GB1010509.6 | 2010-06-22 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/505,039 A-371-Of-International US9023842B2 (en) | 2009-11-05 | 2010-08-06 | Benzodiazepine bromodomain inhibitor |
US14/684,659 Continuation US20150210706A1 (en) | 2009-11-05 | 2015-04-13 | Benzodiazepine Bromodomain Inhibitor |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2011054553A1 true WO2011054553A1 (en) | 2011-05-12 |
Family
ID=42667965
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2010/061518 WO2011054553A1 (en) | 2009-11-05 | 2010-08-06 | Benzodiazepine bromodomain inhibitor |
Country Status (32)
Country | Link |
---|---|
US (3) | US9023842B2 (en) |
EP (3) | EP2722334B1 (en) |
JP (1) | JP5524343B2 (en) |
KR (1) | KR101424989B1 (en) |
CN (1) | CN102762569B (en) |
AU (1) | AU2010314395B2 (en) |
BR (1) | BR112012010706A2 (en) |
CA (1) | CA2779355C (en) |
CL (1) | CL2012001178A1 (en) |
CO (1) | CO6540003A2 (en) |
CR (1) | CR20120283A (en) |
CY (2) | CY1114988T1 (en) |
DK (2) | DK2722334T3 (en) |
DO (1) | DOP2012000114A (en) |
EA (1) | EA020390B1 (en) |
ES (3) | ES2446647T3 (en) |
HK (3) | HK1191012A1 (en) |
HR (2) | HRP20140107T1 (en) |
HU (1) | HUE026421T2 (en) |
IL (2) | IL219090A0 (en) |
MA (1) | MA33803B1 (en) |
ME (1) | ME02360B (en) |
MX (1) | MX2012005295A (en) |
MY (1) | MY160456A (en) |
NZ (1) | NZ599258A (en) |
PE (1) | PE20121181A1 (en) |
PL (2) | PL2722334T3 (en) |
PT (2) | PT2496580E (en) |
RS (2) | RS53179B (en) |
SI (2) | SI2496580T1 (en) |
SM (2) | SMT201400024B (en) |
WO (1) | WO2011054553A1 (en) |
Cited By (75)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013027168A1 (en) | 2011-08-22 | 2013-02-28 | Pfizer Inc. | Novel heterocyclic compounds as bromodomain inhibitors |
WO2013030150A1 (en) | 2011-09-01 | 2013-03-07 | Bayer Intellectual Property Gmbh | 6h-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepines |
WO2014028547A1 (en) | 2012-08-16 | 2014-02-20 | Glaxosmithkline Llc | Benzodiazepines for treating small cell lung cancer |
WO2014076146A1 (en) | 2012-11-13 | 2014-05-22 | Boehringer Ingelheim International Gmbh | Triazolopyridazine |
WO2014076237A1 (en) | 2012-11-16 | 2014-05-22 | Boehringer Ingelheim International Gmbh | Triazolopyrazine |
US8796261B2 (en) | 2010-12-02 | 2014-08-05 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
WO2014134583A2 (en) * | 2013-02-28 | 2014-09-04 | Washington University | Methods of treatment of human cytomegalovirus infection and diseases with bromodomain inhibitors |
WO2014140077A1 (en) * | 2013-03-14 | 2014-09-18 | Glaxosmithkline Intellectual Property (No.2) Limited | Furopyridines as bromodomain inhibitors |
WO2014164771A1 (en) * | 2013-03-11 | 2014-10-09 | Abbvie Inc. | Bromodomain inhibitors |
EP2792355A1 (en) | 2013-04-17 | 2014-10-22 | Albert-Ludwigs-Universität Freiburg | Compounds for use as bromodomain inhibitors |
WO2014173241A1 (en) | 2013-04-26 | 2014-10-30 | Beigene, Ltd. | Substituted5-(3,5-dimethylisoxazol-4-yl)indoline-2-ones |
WO2015013635A2 (en) | 2013-07-25 | 2015-01-29 | Dana-Farber Cancer Institute, Inc. | Inhibitors of transcription factors and uses thereof |
US8980879B2 (en) | 2013-03-11 | 2015-03-17 | Abbvie Inc. | Bromodomain inhibitors |
WO2015067770A1 (en) | 2013-11-07 | 2015-05-14 | Boehringer Ingelheim International Gmbh | Triazolopyrazine derivatives as brd4 inhibitors |
WO2015117087A1 (en) | 2014-01-31 | 2015-08-06 | Dana-Farber Cancer Institute, Inc. | Uses of diazepane derivatives |
WO2015120393A1 (en) * | 2014-02-10 | 2015-08-13 | Concert Pharmaceuticals, Inc. | Substituted triazolobenzodiazepines |
WO2015121230A1 (en) * | 2014-02-14 | 2015-08-20 | Bayer Pharma Aktiengesellschaft | 9-substituted 2,3-benzodiazepines |
WO2015079259A3 (en) * | 2013-11-28 | 2015-08-27 | University Of Dundee | Enzymes functional probes |
US9227985B2 (en) | 2013-03-15 | 2016-01-05 | Incyte Corporation | Tricyclic heterocycles as bet protein inhibitors |
US9249161B2 (en) | 2010-12-02 | 2016-02-02 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
US9290514B2 (en) | 2013-07-08 | 2016-03-22 | Incyte Holdings Corporation | Tricyclic heterocycles as BET protein inhibitors |
US9296741B2 (en) | 2011-12-30 | 2016-03-29 | Abbvie Inc. | Bromodomain inhibitors |
WO2016050821A1 (en) | 2014-10-02 | 2016-04-07 | Glaxosmithkline Intellectual Property (No.2) Limited | Compound |
US9309246B2 (en) | 2013-12-19 | 2016-04-12 | Incyte Corporation | Tricyclic heterocycles as BET protein inhibitors |
US9315501B2 (en) | 2013-11-26 | 2016-04-19 | Incyte Corporation | Bicyclic heterocycles as BET protein inhibitors |
US9328117B2 (en) | 2011-06-17 | 2016-05-03 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
US9399640B2 (en) | 2013-11-26 | 2016-07-26 | Incyte Corporation | Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors |
WO2016123709A1 (en) | 2015-02-03 | 2016-08-11 | Trillium Therapeutics Inc. | Fluorinated imidazo[4,5-c]quinoline derivatives as inhibitors of bromodomain containing proteins |
US9422292B2 (en) | 2011-05-04 | 2016-08-23 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
WO2016146755A1 (en) | 2015-03-19 | 2016-09-22 | Glaxosmithkline Intellectual Property Development Limited | Covalent conjugates of bet inhibitors and alpha amino acid esters |
US9493483B2 (en) | 2012-06-06 | 2016-11-15 | Constellation Pharmaceuticals, Inc. | Benzo [C] isoxazoloazepine bromodomain inhibitors and uses thereof |
US9527864B2 (en) | 2014-09-15 | 2016-12-27 | Incyte Corporation | Tricyclic heterocycles as BET protein inhibitors |
WO2016210275A1 (en) | 2015-06-26 | 2016-12-29 | Tensha Therapeutics, Inc. | Treatment of nut midline carcinoma |
US9540368B2 (en) | 2014-04-23 | 2017-01-10 | Incyte Corporation | 1H-pyrrolo[2,3-c]pyridin-7(6H)-ones and pyrazolo[3,4-c]pyridin-7(6H)-ones as inhibitors of BET proteins |
US9561231B2 (en) | 2012-06-12 | 2017-02-07 | Abbvie Inc. | Pyridinone and pyridazinone derivatives |
US9598420B2 (en) | 2009-11-05 | 2017-03-21 | Glaxosmithkline Llc | Benzodiazepine bromodomain inhibitor |
US9624244B2 (en) | 2012-06-06 | 2017-04-18 | Constellation Pharmaceuticals, Inc. | Benzo [B] isoxazoloazepine bromodomain inhibitors and uses thereof |
US9663523B2 (en) | 2012-09-28 | 2017-05-30 | Bayer Pharma Aktiengesellschaft | BET protein-inhibiting 5-aryltriazoleazepines |
US9695172B2 (en) | 2014-01-31 | 2017-07-04 | Dana-Farber Cancer Institute, Inc. | Diazepane derivatives and uses thereof |
US9714946B2 (en) | 2013-03-14 | 2017-07-25 | Dana-Farber Cancer Institute, Inc. | Bromodomain binding reagents and uses thereof |
EP3104845A4 (en) * | 2014-02-10 | 2017-09-27 | Salk Institute for Biological Studies | Increasing storage of vitamin a, vitamin d and/or lipids |
US9776990B2 (en) | 2012-04-20 | 2017-10-03 | Abbvie Inc. | Isoindolone derivatives |
WO2017059319A3 (en) * | 2015-10-02 | 2017-10-12 | Dana-Farber Cancer Institute, Inc. | Combination therapy of bromodomain inhibitors and checkpoint blockade |
US9789120B2 (en) | 2010-05-14 | 2017-10-17 | Dana-Farber Cancer Institute, Inc. | Male contraceptive compositions and methods of use |
US9890147B2 (en) | 2012-08-16 | 2018-02-13 | Bayer Pharma Aktiengesellshaft | 2,3-benzodiazepines |
US9944650B2 (en) | 2014-07-28 | 2018-04-17 | Astrazeneca Ab | [1,2,4]triazolo[4,3-B]pyridazines for use in the treatment of proliferative diseases |
US9951074B2 (en) | 2014-08-08 | 2018-04-24 | Dana-Farber Cancer Institute, Inc. | Dihydropteridinone derivatives and uses thereof |
US9969747B2 (en) | 2014-06-20 | 2018-05-15 | Constellation Pharmaceuticals, Inc. | Crystalline forms of 2-((4S)-6-(4-chlorophenyl)-1-methyl-4H-benzo[C]isoxazolo[4,5-e]azepin-4-yl)acetamide |
WO2018086605A1 (en) | 2016-11-10 | 2018-05-17 | 山东罗欣药业集团股份有限公司 | Nitrogenous macrocyclic compound, preparation method therefor, pharmaceutical composition and application thereof |
US10124009B2 (en) | 2014-10-27 | 2018-11-13 | Tensha Therapeutics, Inc. | Bromodomain inhibitors |
US10150756B2 (en) | 2014-01-31 | 2018-12-11 | Dana-Farber Cancer Institute, Inc. | Diaminopyrimidine benzenesulfone derivatives and uses thereof |
US10189832B2 (en) | 2016-06-20 | 2019-01-29 | Incyte Corporation | Crystalline solid forms of a BET inhibitor |
US10308653B2 (en) | 2014-08-08 | 2019-06-04 | Dana-Farber Cancer Institute, Inc. | Diazepane derivatives and uses thereof |
US10329305B2 (en) | 2015-10-29 | 2019-06-25 | Incyte Corporation | Amorphous solid form of a BET protein inhibitor |
US10407441B2 (en) | 2010-05-14 | 2019-09-10 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treating neoplasia, inflammatory disease and other disorders |
US10633379B2 (en) | 2016-04-15 | 2020-04-28 | Abbvie Inc. | Bromodomain inhibitors |
US10676484B2 (en) | 2010-05-14 | 2020-06-09 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treating leukemia |
US10702527B2 (en) | 2015-06-12 | 2020-07-07 | Dana-Farber Cancer Institute, Inc. | Combination therapy of transcription inhibitors and kinase inhibitors |
WO2020216779A1 (en) | 2019-04-24 | 2020-10-29 | University Of Dundee | Compounds comprising n-methyl-2-pyridone, and pharmaceutically acceptable salts |
US10881668B2 (en) | 2015-09-11 | 2021-01-05 | Dana-Farber Cancer Institute, Inc. | Acetamide thienotriazolodiazepines and uses thereof |
US10913752B2 (en) | 2015-11-25 | 2021-02-09 | Dana-Farber Cancer Institute, Inc. | Bivalent bromodomain inhibitors and uses thereof |
US10925881B2 (en) | 2014-02-28 | 2021-02-23 | Tensha Therapeutics, Inc. | Treatment of conditions associated with hyperinsulinaemia |
WO2021175432A1 (en) | 2020-03-04 | 2021-09-10 | Boehringer Ingelheim International Gmbh | Method for administration of an anti cancer agent |
WO2021262731A2 (en) | 2020-06-23 | 2021-12-30 | Genentech, Inc. | Macrocyclic compounds and methods of use thereof |
US11306105B2 (en) | 2015-09-11 | 2022-04-19 | Dana-Farber Cancer Institute, Inc. | Cyano thienotriazolodiazepines and uses thereof |
WO2022090699A1 (en) | 2020-10-26 | 2022-05-05 | In4Derm Limited | Pyridone-containing compounds as bromodomain protein inhibitors |
WO2022116968A1 (en) | 2020-12-01 | 2022-06-09 | 成都苑东生物制药股份有限公司 | Novel n-heterocyclic bet bromodomain inhibitor, and preparation method therefor and medical use thereof |
US11446309B2 (en) | 2013-11-08 | 2022-09-20 | Dana-Farber Cancer Institute, Inc. | Combination therapy for cancer using bromodomain and extra-terminal (BET) protein inhibitors |
US11497756B2 (en) | 2017-09-12 | 2022-11-15 | Sumitomo Pharma Oncology, Inc. | Treatment regimen for cancers that are insensitive to BCL-2 inhibitors using the MCL-1 inhibitor alvocidib |
US11530231B2 (en) | 2018-12-04 | 2022-12-20 | Sumitomo Pharma Oncology, Inc. | CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer |
WO2023275542A1 (en) | 2021-06-29 | 2023-01-05 | Tay Therapeutics Limited | Pyrrolopyridone derivatives useful in the treatment of cancer |
US11793802B2 (en) | 2019-03-20 | 2023-10-24 | Sumitomo Pharma Oncology, Inc. | Treatment of acute myeloid leukemia (AML) with venetoclax failure |
WO2023205251A1 (en) | 2022-04-19 | 2023-10-26 | Nuevolution A/S | Compounds active towards bromodomains |
US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
WO2024018423A1 (en) | 2022-07-21 | 2024-01-25 | Tay Therapeutics Limited | Pyrroles and imidazoles as bet protein inhibitors |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0919432D0 (en) * | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Use |
WO2014080291A2 (en) | 2012-11-21 | 2014-05-30 | Rvx Therapeutics Inc. | Biaryl derivatives as bromodomain inhibitors |
US9073878B2 (en) | 2012-11-21 | 2015-07-07 | Zenith Epigenetics Corp. | Cyclic amines as bromodomain inhibitors |
US9271978B2 (en) | 2012-12-21 | 2016-03-01 | Zenith Epigenetics Corp. | Heterocyclic compounds as bromodomain inhibitors |
US9492460B2 (en) * | 2013-02-27 | 2016-11-15 | Bristol-Myers Squibb Company | Carbazole compounds useful as bromodomain inhibitors |
KR20150135359A (en) | 2013-03-14 | 2015-12-02 | 컨버진 엘엘씨 | Methods and compositions for inhibition of bromodomain-containing proteins |
SG11201510409QA (en) | 2013-06-21 | 2016-01-28 | Zenith Epigenetics Corp | Novel bicyclic bromodomain inhibitors |
EP3010917B1 (en) | 2013-06-21 | 2018-01-31 | Zenith Epigenetics Ltd. | Novel substituted bicyclic compounds as bromodomain inhibitors |
AR096758A1 (en) * | 2013-06-28 | 2016-02-03 | Abbvie Inc | BROMODOMINIUM CRYSTAL INHIBITORS |
JP6542212B2 (en) | 2013-07-31 | 2019-07-10 | ゼニス・エピジェネティクス・リミテッドZenith Epigenetics Ltd. | Novel quinazolinones as bromodomain inhibitors |
EP3129378B1 (en) | 2014-04-09 | 2019-06-26 | Kainos Medicine, Inc. | Bromodomain-inhibiting compounds and pharmaceutical composition comprising same for preventing or treating a cancer |
SG11201700776XA (en) * | 2014-08-01 | 2017-02-27 | Nuevolution As | Compounds active towards bromodomains |
US10179125B2 (en) | 2014-12-01 | 2019-01-15 | Zenith Epigenetics Ltd. | Substituted pyridines as bromodomain inhibitors |
CA2966298A1 (en) | 2014-12-01 | 2016-06-09 | Zenith Epigenetics Ltd. | Substituted pyridinones as bromodomain inhibitors |
BR112017011780A2 (en) * | 2014-12-05 | 2017-12-26 | Dana Farber Cancer Inst Inc | bromodomain inhibitor as an auxiliary compound in cancer immunotherapy |
US10292968B2 (en) | 2014-12-11 | 2019-05-21 | Zenith Epigenetics Ltd. | Substituted heterocycles as bromodomain inhibitors |
JP2017538721A (en) | 2014-12-17 | 2017-12-28 | ゼニス・エピジェネティクス・リミテッドZenith Epigenetics Ltd. | Bromodomain inhibitors |
JP6765622B2 (en) | 2015-07-17 | 2020-10-07 | 日本光電工業株式会社 | Lifesaving support device |
EP3490552B1 (en) | 2016-07-26 | 2022-11-23 | University of Southern California | Selective bromodomain inhibition of fungal bdf1 |
CN107759607B (en) * | 2017-11-29 | 2019-08-23 | 上海万巷制药有限公司 | Triazole with anti-tumor activity and phenodiazine Zhuo compound and preparation method thereof |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2242134A (en) | 1990-03-02 | 1991-09-25 | Glaxo Group Ltd | Inhalation device |
US5116971A (en) * | 1986-04-01 | 1992-05-26 | Boehringer Ingelheim Kg | Substituted-1,4-diazepines |
EP0934940A1 (en) * | 1996-06-12 | 1999-08-11 | Japan Tobacco Inc. | Cytokine production inhibitors, triazepine compounds, and intermediates thereof |
WO2005044354A1 (en) | 2003-11-03 | 2005-05-19 | Glaxo Group Limited | A fluid dispensing device |
JP2008156311A (en) | 2006-12-26 | 2008-07-10 | Institute Of Physical & Chemical Research | Brd2 bromodomain binder |
WO2009084693A1 (en) | 2007-12-28 | 2009-07-09 | Mitsubishi Tanabe Pharma Corporation | Antitumor agent |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100255493B1 (en) | 1991-10-11 | 2000-08-01 | 가마쿠라 아키오 | Remedy for osteoporosis and diazepine compounds |
JPH06128257A (en) | 1992-10-13 | 1994-05-10 | Yoshitomi Pharmaceut Ind Ltd | Pyridodiazepine compound |
EP0730596A4 (en) | 1993-11-22 | 1997-07-30 | Merck & Co Inc | Benzodiazepines |
IT1285567B1 (en) | 1996-02-21 | 1998-06-18 | Alfa Chem Ital | NEW PROCESS FOR THE SYNTHESIS OF NABUMETONE |
EP0989131B1 (en) | 1996-09-13 | 2002-11-13 | Mitsubishi Pharma Corporation | Thienotriazolodiazepine compounds and medicinal uses thereof |
JPH11228576A (en) * | 1997-12-10 | 1999-08-24 | Japan Tobacco Inc | Apoptosis inhibitor |
SG115845A1 (en) | 2004-03-31 | 2005-10-28 | Univ Singapore | Modulation of trip-br function and method of treating proliferative disorders |
GB0420970D0 (en) | 2004-09-21 | 2004-10-20 | Smithkline Beecham Corp | Novel triazoloquinoline compounds |
EP1887008B1 (en) | 2005-05-30 | 2021-04-21 | Mitsubishi Tanabe Pharma Corporation | Thienotriazolodiazepine compound and a medicinal use thereof |
GB0919431D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
-
2010
- 2010-08-06 ME MEP-2016-53A patent/ME02360B/en unknown
- 2010-08-06 EP EP13192666.9A patent/EP2722334B1/en active Active
- 2010-08-06 CN CN201080050285.XA patent/CN102762569B/en not_active Expired - Fee Related
- 2010-08-06 MX MX2012005295A patent/MX2012005295A/en active IP Right Grant
- 2010-08-06 EP EP10740654.8A patent/EP2496580B1/en active Active
- 2010-08-06 EP EP16150637.3A patent/EP3037423B1/en active Active
- 2010-08-06 US US13/505,039 patent/US9023842B2/en active Active
- 2010-08-06 MY MYPI2012001967A patent/MY160456A/en unknown
- 2010-08-06 DK DK13192666.9T patent/DK2722334T3/en active
- 2010-08-06 AU AU2010314395A patent/AU2010314395B2/en not_active Ceased
- 2010-08-06 JP JP2012537329A patent/JP5524343B2/en active Active
- 2010-08-06 PL PL13192666T patent/PL2722334T3/en unknown
- 2010-08-06 PT PT107406548T patent/PT2496580E/en unknown
- 2010-08-06 ES ES10740654.8T patent/ES2446647T3/en active Active
- 2010-08-06 KR KR1020127014637A patent/KR101424989B1/en active IP Right Grant
- 2010-08-06 CA CA2779355A patent/CA2779355C/en not_active Expired - Fee Related
- 2010-08-06 BR BR112012010706A patent/BR112012010706A2/en active Search and Examination
- 2010-08-06 NZ NZ599258A patent/NZ599258A/en not_active IP Right Cessation
- 2010-08-06 RS RS20140088A patent/RS53179B/en unknown
- 2010-08-06 RS RS20160102A patent/RS54592B1/en unknown
- 2010-08-06 DK DK10740654.8T patent/DK2496580T3/en active
- 2010-08-06 EA EA201290183A patent/EA020390B1/en not_active IP Right Cessation
- 2010-08-06 PE PE2012000614A patent/PE20121181A1/en not_active Application Discontinuation
- 2010-08-06 PT PT131926669T patent/PT2722334E/en unknown
- 2010-08-06 ES ES13192666.9T patent/ES2563057T3/en active Active
- 2010-08-06 ES ES16150637.3T patent/ES2652304T3/en active Active
- 2010-08-06 SI SI201030514T patent/SI2496580T1/en unknown
- 2010-08-06 SI SI201031117T patent/SI2722334T1/en unknown
- 2010-08-06 WO PCT/EP2010/061518 patent/WO2011054553A1/en active Application Filing
- 2010-08-06 HU HUE13192666A patent/HUE026421T2/en unknown
- 2010-08-06 PL PL10740654T patent/PL2496580T3/en unknown
-
2012
- 2012-04-05 IL IL219090A patent/IL219090A0/en unknown
- 2012-04-18 DO DO2012000114A patent/DOP2012000114A/en unknown
- 2012-05-04 CL CL2012001178A patent/CL2012001178A1/en unknown
- 2012-05-10 CO CO12077201A patent/CO6540003A2/en unknown
- 2012-05-28 CR CR20120283A patent/CR20120283A/en unknown
- 2012-06-04 MA MA34934A patent/MA33803B1/en unknown
-
2013
- 2013-02-21 HK HK14104251.0A patent/HK1191012A1/en not_active IP Right Cessation
- 2013-02-21 HK HK13102225.8A patent/HK1175458A1/en not_active IP Right Cessation
-
2014
- 2014-02-05 HR HRP20140107AT patent/HRP20140107T1/en unknown
- 2014-02-18 CY CY20141100124T patent/CY1114988T1/en unknown
- 2014-02-20 SM SM201400024T patent/SMT201400024B/en unknown
- 2014-11-30 IL IL235983A patent/IL235983B/en active IP Right Grant
-
2015
- 2015-04-13 US US14/684,659 patent/US20150210706A1/en not_active Abandoned
-
2016
- 2016-02-03 HR HRP20160119TT patent/HRP20160119T1/en unknown
- 2016-03-01 CY CY20161100172T patent/CY1117479T1/en unknown
- 2016-03-22 SM SM201600081T patent/SMT201600081B/en unknown
- 2016-07-13 HK HK16108220.7A patent/HK1220188A1/en unknown
-
2017
- 2017-01-20 US US15/410,874 patent/US20170197972A1/en not_active Abandoned
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5116971A (en) * | 1986-04-01 | 1992-05-26 | Boehringer Ingelheim Kg | Substituted-1,4-diazepines |
GB2242134A (en) | 1990-03-02 | 1991-09-25 | Glaxo Group Ltd | Inhalation device |
EP0934940A1 (en) * | 1996-06-12 | 1999-08-11 | Japan Tobacco Inc. | Cytokine production inhibitors, triazepine compounds, and intermediates thereof |
WO2005044354A1 (en) | 2003-11-03 | 2005-05-19 | Glaxo Group Limited | A fluid dispensing device |
JP2008156311A (en) | 2006-12-26 | 2008-07-10 | Institute Of Physical & Chemical Research | Brd2 bromodomain binder |
WO2009084693A1 (en) | 2007-12-28 | 2009-07-09 | Mitsubishi Tanabe Pharma Corporation | Antitumor agent |
Non-Patent Citations (11)
Title |
---|
BERGE ET AL., J. PHARM. SCI., vol. 66, 1977, pages 1 - 19 |
FRENCH ET AL., CANCER RESEARCH, vol. 63, 2003, pages 304 - 307 |
FRENCH ET AL., JOURNAL OF CLINICAL ONCOLOGY, vol. 22, no. 20, 2004, pages 4135 - 4139 |
HARGREAVES ET AL., CELL, vol. 2009138, no. 1, pages 129 - 145 |
INT. J. PEPTIDE PROTEIN RES., vol. 40, 1992, pages 13 - 18 |
J. CHEM. SOC. PERKIN TRANS., vol. 1, 2001, pages 1673 - 1695 |
J. ORG. CHEM., vol. 55, 1990, pages 3068 - 3074 |
LEROY ET AL., MOL. CELL, vol. 30, no. 1, 2008, pages 51 - 60 |
ONCOGENE, vol. 27, 2008, pages 2237 - 2242 |
SYNTHESIS, 1980, pages 677 - 688 |
YOU ET AL., CELL, vol. 117, no. 3, 2004, pages 349 - 60 |
Cited By (129)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9598420B2 (en) | 2009-11-05 | 2017-03-21 | Glaxosmithkline Llc | Benzodiazepine bromodomain inhibitor |
US9789120B2 (en) | 2010-05-14 | 2017-10-17 | Dana-Farber Cancer Institute, Inc. | Male contraceptive compositions and methods of use |
US10407441B2 (en) | 2010-05-14 | 2019-09-10 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treating neoplasia, inflammatory disease and other disorders |
US10676484B2 (en) | 2010-05-14 | 2020-06-09 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treating leukemia |
US8796261B2 (en) | 2010-12-02 | 2014-08-05 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
US9249161B2 (en) | 2010-12-02 | 2016-02-02 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
US9522920B2 (en) | 2010-12-02 | 2016-12-20 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
US9422292B2 (en) | 2011-05-04 | 2016-08-23 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
US9328117B2 (en) | 2011-06-17 | 2016-05-03 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
WO2013027168A1 (en) | 2011-08-22 | 2013-02-28 | Pfizer Inc. | Novel heterocyclic compounds as bromodomain inhibitors |
DE102011082013A1 (en) | 2011-09-01 | 2013-03-07 | Bayer Pharma AG | 6H-thieno [3,2-f] [1,2,4] triazolo [4,3-a] [1,4] diazepines |
WO2013030150A1 (en) | 2011-09-01 | 2013-03-07 | Bayer Intellectual Property Gmbh | 6h-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepines |
US9296741B2 (en) | 2011-12-30 | 2016-03-29 | Abbvie Inc. | Bromodomain inhibitors |
US9776990B2 (en) | 2012-04-20 | 2017-10-03 | Abbvie Inc. | Isoindolone derivatives |
US9624244B2 (en) | 2012-06-06 | 2017-04-18 | Constellation Pharmaceuticals, Inc. | Benzo [B] isoxazoloazepine bromodomain inhibitors and uses thereof |
US9493483B2 (en) | 2012-06-06 | 2016-11-15 | Constellation Pharmaceuticals, Inc. | Benzo [C] isoxazoloazepine bromodomain inhibitors and uses thereof |
US9925197B2 (en) | 2012-06-06 | 2018-03-27 | Constellation Pharmaceuticals, Inc. | Benzo [C] isoxazoloazepine bromodomain inhibitors and uses thereof |
US9561231B2 (en) | 2012-06-12 | 2017-02-07 | Abbvie Inc. | Pyridinone and pyridazinone derivatives |
JP2015524847A (en) * | 2012-08-16 | 2015-08-27 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーGlaxoSmithKline LLC | Benzodiazepines for treating small cell lung cancer |
CN104582708A (en) * | 2012-08-16 | 2015-04-29 | 葛兰素史克有限责任公司 | Benzodiazepines for treating small cell lung cancer |
AU2013302766B2 (en) * | 2012-08-16 | 2016-10-20 | Glaxosmithkline Llc | Benzodiazepines for treating small cell lung cancer |
US9890147B2 (en) | 2012-08-16 | 2018-02-13 | Bayer Pharma Aktiengesellshaft | 2,3-benzodiazepines |
WO2014028547A1 (en) | 2012-08-16 | 2014-02-20 | Glaxosmithkline Llc | Benzodiazepines for treating small cell lung cancer |
US9663523B2 (en) | 2012-09-28 | 2017-05-30 | Bayer Pharma Aktiengesellschaft | BET protein-inhibiting 5-aryltriazoleazepines |
US9422290B2 (en) | 2012-11-13 | 2016-08-23 | Boehringer Ingelheim International Gmbh | Triazolopyridazine |
WO2014076146A1 (en) | 2012-11-13 | 2014-05-22 | Boehringer Ingelheim International Gmbh | Triazolopyridazine |
US11077107B2 (en) | 2012-11-16 | 2021-08-03 | Boehringer Ingelheim International Gmbh | Triazolopyrazine |
US10328074B2 (en) | 2012-11-16 | 2019-06-25 | Boehringer Ingelheim International Gmbh | Substituted [1,2,4]triazolo[4,3-a]pyrazines as BRD4 inhibitors |
WO2014076237A1 (en) | 2012-11-16 | 2014-05-22 | Boehringer Ingelheim International Gmbh | Triazolopyrazine |
WO2014134583A3 (en) * | 2013-02-28 | 2014-11-06 | Washington University | Methods of treatment of human cytomegalovirus infection and diseases with bromodomain inhibitors |
WO2014134583A2 (en) * | 2013-02-28 | 2014-09-04 | Washington University | Methods of treatment of human cytomegalovirus infection and diseases with bromodomain inhibitors |
US8980879B2 (en) | 2013-03-11 | 2015-03-17 | Abbvie Inc. | Bromodomain inhibitors |
US9050346B2 (en) | 2013-03-11 | 2015-06-09 | Abbvie Inc. | Bromodomain inhibitors |
WO2014164771A1 (en) * | 2013-03-11 | 2014-10-09 | Abbvie Inc. | Bromodomain inhibitors |
WO2014140077A1 (en) * | 2013-03-14 | 2014-09-18 | Glaxosmithkline Intellectual Property (No.2) Limited | Furopyridines as bromodomain inhibitors |
US9714946B2 (en) | 2013-03-14 | 2017-07-25 | Dana-Farber Cancer Institute, Inc. | Bromodomain binding reagents and uses thereof |
RU2655727C2 (en) * | 2013-03-14 | 2018-05-30 | ГлаксоСмитКлайн Интеллекчуал Проперти (N2) Лимитед | Furopyridines as bromodomain inhibitors |
US9670221B2 (en) | 2013-03-14 | 2017-06-06 | Glaxosmithkline Intellectual Property (No. 2) Limited | Furopyridines as bromodomain inhibitors |
AU2014230816B2 (en) * | 2013-03-14 | 2016-12-01 | Glaxosmithkline Intellectual Property (No.2) Limited | Furopyridines as bromodomain inhibitors |
RU2655727C9 (en) * | 2013-03-14 | 2018-07-06 | ГлаксоСмитКлайн Интеллекчуал Проперти (N2) Лимитед | Furopyridines as bromodomain inhibitors |
US9624241B2 (en) | 2013-03-15 | 2017-04-18 | Incyte Corporation | Tricyclic heterocycles as BET protein inhibitors |
US9227985B2 (en) | 2013-03-15 | 2016-01-05 | Incyte Corporation | Tricyclic heterocycles as bet protein inhibitors |
US11498926B2 (en) | 2013-03-15 | 2022-11-15 | Incyte Corporation | Tricyclic heterocycles as BET protein inhibitors |
US9938294B2 (en) | 2013-03-15 | 2018-04-10 | Incyte Corporation | Tricyclic heterocycles as BET protein inhibitors |
US10464947B2 (en) | 2013-03-15 | 2019-11-05 | Incyte Holdings Corporation | Tricyclic heterocycles as BET protein inhibitors |
US10919912B2 (en) | 2013-03-15 | 2021-02-16 | Incyte Holdings Corporation | Tricyclic heterocycles as BET protein inhibitors |
EP2792355A1 (en) | 2013-04-17 | 2014-10-22 | Albert-Ludwigs-Universität Freiburg | Compounds for use as bromodomain inhibitors |
WO2014173241A1 (en) | 2013-04-26 | 2014-10-30 | Beigene, Ltd. | Substituted5-(3,5-dimethylisoxazol-4-yl)indoline-2-ones |
US9533997B2 (en) | 2013-07-08 | 2017-01-03 | Incyte Holdings Corporation | Tricyclic heterocycles as BET protein inhibitors |
US9290514B2 (en) | 2013-07-08 | 2016-03-22 | Incyte Holdings Corporation | Tricyclic heterocycles as BET protein inhibitors |
US9850257B2 (en) | 2013-07-08 | 2017-12-26 | Incyte Corporation | Tricyclic heterocycles as BET protein inhibitors |
US9975896B2 (en) | 2013-07-25 | 2018-05-22 | Dana-Farber Cancer Institute, Inc. | Inhibitors of transcription factors and uses thereof |
WO2015013635A2 (en) | 2013-07-25 | 2015-01-29 | Dana-Farber Cancer Institute, Inc. | Inhibitors of transcription factors and uses thereof |
WO2015067770A1 (en) | 2013-11-07 | 2015-05-14 | Boehringer Ingelheim International Gmbh | Triazolopyrazine derivatives as brd4 inhibitors |
US11446309B2 (en) | 2013-11-08 | 2022-09-20 | Dana-Farber Cancer Institute, Inc. | Combination therapy for cancer using bromodomain and extra-terminal (BET) protein inhibitors |
US9918990B2 (en) | 2013-11-26 | 2018-03-20 | Incyte Corporation | Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors |
US9737516B2 (en) | 2013-11-26 | 2017-08-22 | Incyte Corporation | Bicyclic heterocycles as bet protein inhibitors |
US9315501B2 (en) | 2013-11-26 | 2016-04-19 | Incyte Corporation | Bicyclic heterocycles as BET protein inhibitors |
US9399640B2 (en) | 2013-11-26 | 2016-07-26 | Incyte Corporation | Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors |
WO2015079259A3 (en) * | 2013-11-28 | 2015-08-27 | University Of Dundee | Enzymes functional probes |
US9309246B2 (en) | 2013-12-19 | 2016-04-12 | Incyte Corporation | Tricyclic heterocycles as BET protein inhibitors |
US9777003B2 (en) | 2013-12-19 | 2017-10-03 | Incyte Corporation | Tricyclic heterocycles as bet protein inhibitors |
US11091484B2 (en) | 2013-12-19 | 2021-08-17 | Incyte Corporation | Tricyclic heterocycles as BET protein inhibitors |
US10442803B2 (en) | 2013-12-19 | 2019-10-15 | Incyte Corporation | Tricyclic heterocycles as bet protein inhibitors |
US9695172B2 (en) | 2014-01-31 | 2017-07-04 | Dana-Farber Cancer Institute, Inc. | Diazepane derivatives and uses thereof |
WO2015117087A1 (en) | 2014-01-31 | 2015-08-06 | Dana-Farber Cancer Institute, Inc. | Uses of diazepane derivatives |
US10150756B2 (en) | 2014-01-31 | 2018-12-11 | Dana-Farber Cancer Institute, Inc. | Diaminopyrimidine benzenesulfone derivatives and uses thereof |
US10730860B2 (en) | 2014-01-31 | 2020-08-04 | Dana-Farber Cancer Institute, Inc. | Diaminopyrimidine benzenesulfone derivatives and uses thereof |
US10793571B2 (en) | 2014-01-31 | 2020-10-06 | Dana-Farber Cancer Institute, Inc. | Uses of diazepane derivatives |
EP3104845A4 (en) * | 2014-02-10 | 2017-09-27 | Salk Institute for Biological Studies | Increasing storage of vitamin a, vitamin d and/or lipids |
US9694017B2 (en) | 2014-02-10 | 2017-07-04 | Concert Pharmaceuticals, Inc. | Substituted triazolobenzodiazepines |
US10357499B2 (en) | 2014-02-10 | 2019-07-23 | Concert Pharmaceutical, Inc. | Substituted triazolobenzodiazepines |
WO2015120393A1 (en) * | 2014-02-10 | 2015-08-13 | Concert Pharmaceuticals, Inc. | Substituted triazolobenzodiazepines |
JP2017505821A (en) * | 2014-02-10 | 2017-02-23 | コンサート ファーマシューティカルズ インコーポレイテッド | Substituted triazolobenzodiazepines |
US10039769B2 (en) | 2014-02-10 | 2018-08-07 | Concert Pharmaceuticals, Inc. | Substituted triazolobenzodiazepines |
WO2015121230A1 (en) * | 2014-02-14 | 2015-08-20 | Bayer Pharma Aktiengesellschaft | 9-substituted 2,3-benzodiazepines |
US10925881B2 (en) | 2014-02-28 | 2021-02-23 | Tensha Therapeutics, Inc. | Treatment of conditions associated with hyperinsulinaemia |
US10781209B2 (en) | 2014-04-23 | 2020-09-22 | Incyte Corporation | 1H-pyrrolo[2,3-c]pyridin-7(6H)-ones and pyrazolo[3,4-c]pyridin-7(6H)-ones as inhibitors of BET proteins |
US9540368B2 (en) | 2014-04-23 | 2017-01-10 | Incyte Corporation | 1H-pyrrolo[2,3-c]pyridin-7(6H)-ones and pyrazolo[3,4-c]pyridin-7(6H)-ones as inhibitors of BET proteins |
US11059821B2 (en) | 2014-04-23 | 2021-07-13 | Incyte Corporation | 1H-pyrrolo[2,3-c]pyridin-7(6H)-ones and pyrazolo[3,4-c]pyridin-7(6H)-ones as inhibitors of BET proteins |
US10472358B2 (en) | 2014-04-23 | 2019-11-12 | Incyte Corporation | 1H-pyrrolo[2,3-c]pyridin-7(6H)-ones and pyrazolo[3,4-c]pyridin-7(6H)-ones as inhibitors of BET proteins |
US9957268B2 (en) | 2014-04-23 | 2018-05-01 | Incyte Corporation | 1H-pyrrolo[2,3,c]pyridin-7(6H)-ones and pyrazolo[3,4-c]pyridin-7(6H)-ones as inhibitors of BET proteins |
US11702416B2 (en) | 2014-04-23 | 2023-07-18 | Incyte Corporation | 1H-pyrrolo[2,3-c]pyridin-7(6H)-ones and pyrazolo[3,4-c]pyridin-7(6H)-ones as inhibitors of BET proteins |
US9969747B2 (en) | 2014-06-20 | 2018-05-15 | Constellation Pharmaceuticals, Inc. | Crystalline forms of 2-((4S)-6-(4-chlorophenyl)-1-methyl-4H-benzo[C]isoxazolo[4,5-e]azepin-4-yl)acetamide |
US9944650B2 (en) | 2014-07-28 | 2018-04-17 | Astrazeneca Ab | [1,2,4]triazolo[4,3-B]pyridazines for use in the treatment of proliferative diseases |
US10766905B2 (en) | 2014-07-28 | 2020-09-08 | Astrazeneca Ab | [1,2,4]triazolo[4,3-B]pyridazines for use in the treatment of proliferative diseases |
US10407432B2 (en) | 2014-07-28 | 2019-09-10 | Astrazeneca Ab | [1,2,4]triazolo[4,3-B]pyridazines for use in the treatment of proliferative diseases |
US11407755B2 (en) | 2014-07-28 | 2022-08-09 | Astrazeneca Ab | [1,2,4]triazolo[4,3-b]pyridazines for use in the treatment of proliferative diseases |
US10308653B2 (en) | 2014-08-08 | 2019-06-04 | Dana-Farber Cancer Institute, Inc. | Diazepane derivatives and uses thereof |
US9951074B2 (en) | 2014-08-08 | 2018-04-24 | Dana-Farber Cancer Institute, Inc. | Dihydropteridinone derivatives and uses thereof |
US9527864B2 (en) | 2014-09-15 | 2016-12-27 | Incyte Corporation | Tricyclic heterocycles as BET protein inhibitors |
US10227359B2 (en) | 2014-09-15 | 2019-03-12 | Incyte Corporation | Tricyclic heterocycles as bet protein inhibitors |
US10618910B2 (en) | 2014-09-15 | 2020-04-14 | Incyte Corporation | Tricyclic heterocycles as BET protein inhibitors |
US9834565B2 (en) | 2014-09-15 | 2017-12-05 | Incyte Corporation | Tricyclic heterocycles as bet protein inhibitors |
AU2015326910B2 (en) * | 2014-10-02 | 2018-03-01 | Glaxosmithkline Intellectual Property (No.2) Limited | Compound |
WO2016050821A1 (en) | 2014-10-02 | 2016-04-07 | Glaxosmithkline Intellectual Property (No.2) Limited | Compound |
US9975901B2 (en) | 2014-10-02 | 2018-05-22 | Glaxosmithkline Intellectual Property (No. 2) Limited | Crystalline solid state form of the benzene sulphonic acid salt of 2-[(4S)-6-(4-chlorophenyl)-1-methyl-8-(methyloxy)-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-4-yl]-N-ethylacetamide |
US10450319B2 (en) | 2014-10-02 | 2019-10-22 | Glaxosmithkline Intellectual Property (No.2) Limited | Pharmaceutical compositions of compound |
US10124009B2 (en) | 2014-10-27 | 2018-11-13 | Tensha Therapeutics, Inc. | Bromodomain inhibitors |
WO2016123709A1 (en) | 2015-02-03 | 2016-08-11 | Trillium Therapeutics Inc. | Fluorinated imidazo[4,5-c]quinoline derivatives as inhibitors of bromodomain containing proteins |
WO2016146755A1 (en) | 2015-03-19 | 2016-09-22 | Glaxosmithkline Intellectual Property Development Limited | Covalent conjugates of bet inhibitors and alpha amino acid esters |
US10702527B2 (en) | 2015-06-12 | 2020-07-07 | Dana-Farber Cancer Institute, Inc. | Combination therapy of transcription inhibitors and kinase inhibitors |
WO2016210275A1 (en) | 2015-06-26 | 2016-12-29 | Tensha Therapeutics, Inc. | Treatment of nut midline carcinoma |
US10881668B2 (en) | 2015-09-11 | 2021-01-05 | Dana-Farber Cancer Institute, Inc. | Acetamide thienotriazolodiazepines and uses thereof |
US11406645B2 (en) | 2015-09-11 | 2022-08-09 | Dana-Farber Cancer Institute, Inc. | Acetamide thienotriazolodiazepines and uses thereof |
US11306105B2 (en) | 2015-09-11 | 2022-04-19 | Dana-Farber Cancer Institute, Inc. | Cyano thienotriazolodiazepines and uses thereof |
WO2017059319A3 (en) * | 2015-10-02 | 2017-10-12 | Dana-Farber Cancer Institute, Inc. | Combination therapy of bromodomain inhibitors and checkpoint blockade |
US10329305B2 (en) | 2015-10-29 | 2019-06-25 | Incyte Corporation | Amorphous solid form of a BET protein inhibitor |
US10858372B2 (en) | 2015-10-29 | 2020-12-08 | Incyte Corporation | Amorphous solid form of a BET protein inhibitor |
US10913752B2 (en) | 2015-11-25 | 2021-02-09 | Dana-Farber Cancer Institute, Inc. | Bivalent bromodomain inhibitors and uses thereof |
US10633379B2 (en) | 2016-04-15 | 2020-04-28 | Abbvie Inc. | Bromodomain inhibitors |
US10189832B2 (en) | 2016-06-20 | 2019-01-29 | Incyte Corporation | Crystalline solid forms of a BET inhibitor |
US10626114B2 (en) | 2016-06-20 | 2020-04-21 | Incyte Corporation | Crystalline solid forms of a BET inhibitor |
US11091480B2 (en) | 2016-06-20 | 2021-08-17 | Incyte Corporation | Crystalline solid forms of a BET inhibitor |
US11377446B2 (en) | 2016-06-20 | 2022-07-05 | Incyte Corporation | Crystalline solid forms of a BET inhibitor |
WO2018086605A1 (en) | 2016-11-10 | 2018-05-17 | 山东罗欣药业集团股份有限公司 | Nitrogenous macrocyclic compound, preparation method therefor, pharmaceutical composition and application thereof |
US11497756B2 (en) | 2017-09-12 | 2022-11-15 | Sumitomo Pharma Oncology, Inc. | Treatment regimen for cancers that are insensitive to BCL-2 inhibitors using the MCL-1 inhibitor alvocidib |
US11530231B2 (en) | 2018-12-04 | 2022-12-20 | Sumitomo Pharma Oncology, Inc. | CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer |
US11793802B2 (en) | 2019-03-20 | 2023-10-24 | Sumitomo Pharma Oncology, Inc. | Treatment of acute myeloid leukemia (AML) with venetoclax failure |
WO2020216779A1 (en) | 2019-04-24 | 2020-10-29 | University Of Dundee | Compounds comprising n-methyl-2-pyridone, and pharmaceutically acceptable salts |
WO2021175824A1 (en) | 2020-03-04 | 2021-09-10 | Boehringer Ingelheim International Gmbh | Method for administration of an anti cancer agent |
WO2021175432A1 (en) | 2020-03-04 | 2021-09-10 | Boehringer Ingelheim International Gmbh | Method for administration of an anti cancer agent |
US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
WO2021262731A2 (en) | 2020-06-23 | 2021-12-30 | Genentech, Inc. | Macrocyclic compounds and methods of use thereof |
WO2022090699A1 (en) | 2020-10-26 | 2022-05-05 | In4Derm Limited | Pyridone-containing compounds as bromodomain protein inhibitors |
WO2022116968A1 (en) | 2020-12-01 | 2022-06-09 | 成都苑东生物制药股份有限公司 | Novel n-heterocyclic bet bromodomain inhibitor, and preparation method therefor and medical use thereof |
WO2023275542A1 (en) | 2021-06-29 | 2023-01-05 | Tay Therapeutics Limited | Pyrrolopyridone derivatives useful in the treatment of cancer |
WO2023205251A1 (en) | 2022-04-19 | 2023-10-26 | Nuevolution A/S | Compounds active towards bromodomains |
WO2024018423A1 (en) | 2022-07-21 | 2024-01-25 | Tay Therapeutics Limited | Pyrroles and imidazoles as bet protein inhibitors |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3037423B1 (en) | Novel benzodiazepine compound | |
EP3050885B1 (en) | Benzodiazepine bromodomain inhibitor | |
EP2585465B1 (en) | Benzotriazolodiazepine compounds inhibitors of bromodomains | |
EP2705032B1 (en) | Dihydroquinoline derivatives as bromodomain inhibitors | |
US20120208800A1 (en) | Bromodomain Inhibitors For Treating Autoimmune And Inflammatory Diseases | |
US20120202799A1 (en) | Condensed Azepine Derivatives As Bromodomain Inhibitors | |
AU2015203454B2 (en) | Benzodiazepine bromodomain inhibitor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201080050285.X Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10740654 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 219090 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 3735/DELNP/2012 Country of ref document: IN Ref document number: 2010740654 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010314395 Country of ref document: AU Ref document number: 2779355 Country of ref document: CA Ref document number: 13505039 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012537329 Country of ref document: JP Ref document number: 201290183 Country of ref document: EA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 000614-2012 Country of ref document: PE Ref document number: 12012500894 Country of ref document: PH Ref document number: MX/A/2012/005295 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1201002078 Country of ref document: TH |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12077201 Country of ref document: CO |
|
WWE | Wipo information: entry into national phase |
Ref document number: A201205470 Country of ref document: UA |
|
ENP | Entry into the national phase |
Ref document number: 2010314395 Country of ref document: AU Date of ref document: 20100806 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: CR2012-000283 Country of ref document: CR |
|
ENP | Entry into the national phase |
Ref document number: 20127014637 Country of ref document: KR Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112012010706 Country of ref document: BR |
|
WWE | Wipo information: entry into national phase |
Ref document number: P-2014/0088 Country of ref document: RS |
|
WWE | Wipo information: entry into national phase |
Ref document number: 235983 Country of ref document: IL |
|
ENP | Entry into the national phase |
Ref document number: 112012010706 Country of ref document: BR Kind code of ref document: A2 Effective date: 20120504 |